Focus: Arch Therapeutics is a medical device company focused on surgical hemostats and fluid leakage prevention, with a nascent oncology pipeline. The company operates at a modest scale with minimal disclosed staffing and early-stage development programs.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Arch Therapeutics presents a high-risk, early-stage opportunity suitable only for founders-minded professionals comfortable with uncertainty and limited near-term visibility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Arch Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Arch Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo